Grace Therapeutics, Inc. Financing Cash Flow
Grace Therapeutics, Inc. (GRCE) reported Financing Cash Flow of $0 for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-13
- Grace Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $0.00.
- Grace Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- Grace Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $4.04M.
- Grace Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $0.00.
- Grace Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2026 was $3.71M, a 73.54% decline from fiscal 2025.
- Grace Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2025 was $14.03M, a 90.68% increase from fiscal 2024.
- Grace Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2024 was $7.36M, a 2320.72% increase from fiscal 2023.
- Grace Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2023 was $304.00K.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 3 month as first filed | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-13 | $0.00 derived: sum of 2 quarters · filed 2026-08-13 | $4.04M derived: sum of 3 quarters · filed 2026-08-13 | $4.04M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2026-03-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-18 | $4.04M derived: sum of 2 quarters · filed 2026-06-18 | $4.04M derived: sum of 3 quarters · filed 2026-06-18 | $3.71M 10-K · filed 2026-06-18 | |
| 2025-12-31 | $4.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-02-12 | $4.04M derived: sum of 2 quarters · filed 2026-02-12 | $3.71M 10-Q · filed 2026-02-12 | $17.75M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-09-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-11-13 | -$327.00K 10-Q · filed 2025-11-13 | $13.71M derived: sum of 3 quarters · filed 2026-08-13 | $13.71M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-06-30 | -$327.00K 10-Q · filed 2026-08-13 | $13.71M derived: sum of 2 quarters · filed 2026-08-13 | $13.71M derived: sum of 3 quarters · filed 2026-08-13 | $13.71M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-03-31 | $14.03M derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-18 | $14.03M derived: sum of 2 quarters · filed 2026-06-18 | $14.03M derived: sum of 3 quarters · filed 2026-06-18 | $14.03M 10-K · filed 2026-06-18 | |
| 2024-12-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2026-02-12 | $0.00 derived: sum of 2 quarters · filed 2026-02-12 | $0.00 10-Q · filed 2026-02-12 | $0.00 derived: sum of 4 quarters · filed 2026-02-12 | |
| 2024-09-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-11-13 | $0.00 10-Q · filed 2025-11-13 | $0.00 derived: sum of 3 quarters · filed 2025-11-13 | $0.00 derived: sum of 4 quarters · filed 2025-11-13 | |
| 2024-06-30 | $0.00 10-Q · filed 2025-08-12 | $0.00 derived: sum of 2 quarters · filed 2025-08-12 | $0.00 derived: sum of 3 quarters · filed 2025-08-12 | $7.36M derived: sum of 4 quarters · filed 2025-08-12 | |
| 2024-03-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-06-23 | $0.00 derived: sum of 2 quarters · filed 2025-06-23 | $7.36M derived: sum of 3 quarters · filed 2025-06-23 | $7.36M 10-K · filed 2025-06-23 | |
| 2023-12-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-02-13 | $7.36M derived: sum of 2 quarters · filed 2025-02-13 | $7.36M 10-Q · filed 2025-02-13 | $7.36M derived: sum of 4 quarters · filed 2025-02-13 | |
| 2023-09-30 | $7.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-11-13 | $7.36M 10-Q · filed 2024-11-13 | $7.36M derived: sum of 3 quarters · filed 2024-11-13 | $7.36M derived: sum of 4 quarters · filed 2024-11-13 | |
| 2023-06-30 | $0.00 10-Q · filed 2023-08-11 | $0.00 derived: sum of 2 quarters · filed 2024-06-21 | $0.00 derived: sum of 3 quarters · filed 2024-06-21 | $109.00K derived: sum of 4 quarters · filed 2024-06-21 | |
| 2023-03-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-06-21 | $0.00 derived: sum of 2 quarters · filed 2024-06-21 | $109.00K derived: sum of 3 quarters · filed 2024-06-21 | $304.00K 10-K · filed 2024-06-21 | |
| 2022-12-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-02-12 | $109.00K derived: sum of 2 quarters · filed 2024-02-12 | $304.00K 10-Q · filed 2024-02-12 | $304.00K derived: sum of 4 quarters · filed 2024-02-12 | |
| 2022-09-30 | $109.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-11-13 | $304.00K 10-Q · filed 2023-11-13 | $304.00K derived: sum of 3 quarters · filed 2023-11-13 | $304.00K derived: sum of 4 quarters · filed 2023-11-13 | |
| 2022-06-30 | $195.00K 10-Q · filed 2023-08-11 | $195.00K derived: sum of 2 quarters · filed 2023-08-11 | $195.00K derived: sum of 3 quarters · filed 2023-08-11 | $195.00K derived: sum of 4 quarters · filed 2023-08-11 | |
| 2022-03-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-06-23 | $0.00 derived: sum of 2 quarters · filed 2023-06-23 | $0.00 derived: sum of 3 quarters · filed 2023-06-23 | $0.00 10-K · filed 2023-06-23 | |
| 2021-12-31 | $0.00 10-Q · filed 2022-02-14 | $0.00 derived: sum of 2 quarters · filed 2022-02-14 | $0.00 10-Q · filed 2023-02-14 | $34.68M derived: sum of 4 quarters · filed 2022-08-11 | |
| 2021-09-30 | $0.00 10-Q · filed 2021-11-10 | $0.00 10-Q · filed 2021-11-10 | $34.68M derived: sum of 3 quarters · filed 2022-08-11 | $54.42M derived: sum of 4 quarters · filed 2022-08-11 | |
| 2021-06-30 | $0.00 10-Q · filed 2022-08-11 | $34.68M derived: sum of 2 quarters · filed 2022-08-11 | $54.42M derived: sum of 3 quarters · filed 2022-08-11 | $57.86M derived: sum of 4 quarters · filed 2022-08-11 | |
| 2021-03-31 | $34.68M derived: 10-K 12 month − 10-Q 9 month · filed 2022-06-21 | $54.42M derived: sum of 2 quarters · filed 2022-06-21 | $57.86M derived: sum of 3 quarters · filed 2022-06-21 | $59.49M 10-K · filed 2022-06-21 | |
| 2020-12-31 | $19.75M 10-Q · filed 2022-02-14 | $23.18M derived: sum of 2 quarters · filed 2022-02-14 | $24.81M 10-Q · filed 2022-02-14 | $37.99M derived: sum of 4 quarters · filed 2022-02-14 | |
| 2020-09-30 | $3.43M 10-Q · filed 2021-11-10 | $5.07M 10-Q · filed 2021-11-10 | $18.25M derived: sum of 3 quarters · filed 2021-11-10 | $25.36M derived: sum of 4 quarters · filed 2021-11-10 | |
| 2020-06-30 | $1.64M 10-Q · filed 2021-08-12 | $1.77M 10-Q · filed 2020-08-13 | $14.81M derived: sum of 2 quarters · filed 2021-08-12 | $21.93M derived: sum of 3 quarters · filed 2021-08-12 | $28.52M derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | $13.18M 10-K · filed 2020-06-29 | $20.29M derived: sum of 2 quarters · filed 2021-02-09 | $26.89M derived: sum of 3 quarters · filed 2021-02-09 | $13.18M 10-K · filed 2021-06-22 | |
| 2019-12-31 | $7.12M 10-Q · filed 2021-02-09 | $13.71M derived: sum of 2 quarters · filed 2021-02-09 | $13.71M 10-Q · filed 2021-02-09 | $59.44M derived: sum of 4 quarters · filed 2021-02-09 | |
| 2019-09-30 | $6.60M 10-Q · filed 2020-11-16 | $6.60M 10-Q · filed 2020-11-16 | $52.32M derived: sum of 3 quarters · filed 2020-11-16 | ||
| 2019-06-30 | $34.00K 10-Q · filed 2020-08-13 | $45.72M derived: sum of 2 quarters · filed 2020-08-13 | |||
| 2019-03-31 | $45.69M 10-K · filed 2020-06-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |